Monte Rosa CMO sells 9,189 company shares

Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock.

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an open-market sale of company stock. On February 23, 2026, he sold 9,189 shares of common stock at an average price of $19.4973 per share and now directly owns 65,837 shares.

Insider Trade Summary

Net Seller: 9,189 shares

Net Sell 1 txn

Insider Janku Filip

Role Chief Medical Officer

Sold 9,189 shs ($179K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,189	$19.4973	$179K

Holdings After Transaction: Common Stock — 65,837 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Monte Rosa Therapeutics (GLUE) disclose for Filip Janku?

Monte Rosa Therapeutics disclosed that Chief Medical Officer Filip Janku sold 9,189 shares of common stock. The transaction occurred on February 23, 2026, as an open-market sale at an average price of $19.4973 per share, and was reported on a Form 4 insider filing.

How many Monte Rosa Therapeutics shares did the CMO sell and at what price?

Chief Medical Officer Filip Janku sold 9,189 shares of Monte Rosa Therapeutics common stock. The sale was executed in the open market at an average price of $19.4973 per share, according to the Form 4 insider trading report filed for ticker GLUE.

How many Monte Rosa Therapeutics (GLUE) shares does Filip Janku own after this sale?

After the reported transaction, Chief Medical Officer Filip Janku directly owns 65,837 shares of Monte Rosa Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership following the open-market sale of 9,189 shares disclosed in the Form 4 filing.

What does the Form 4 filing reveal about the nature of the GLUE stock transaction?

The Form 4 filing shows the transaction was an open-market sale of Monte Rosa Therapeutics common stock. It is classified with code “S,” indicating a sale in the open market or a private transaction, and is categorized as a non-derivative common stock trade.

Who is the insider involved in the latest Monte Rosa Therapeutics Form 4 filing?

The insider is Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics. He is listed as an officer, not a director or 10% owner, and reported selling 9,189 shares of common stock while retaining 65,837 shares as direct ownership after the transaction.

Does the Monte Rosa Therapeutics Form 4 filing show a net buy or net sell position?

The Form 4 filing shows a net sell position for the reporting period. It reports one sale transaction totaling 9,189 shares sold and no purchases, resulting in a net change of negative 9,189 shares for Chief Medical Officer Filip Janku’s directly held common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/24/2026 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Janku Filip

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

02118

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/23/2026		S		9,189	D	$19.4973	65,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Markus Warmuth, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR